Evaluation of the effects of 3 successive oral dosages (2.5; 5; 7.5 mg b.i.d.) of ivabradine in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers. A 9 week pilot, open labelled, international multicenter study

Registry ID

EUCTR2005-000103-34

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Institut de Recherches Internationales Servier

Start date

2005-06-16

Completion date

2007-01-31

Last update

2026-08-16

Conditions

• Chronic Heart Failure
• Chronic systolic heart failure

Summary

The primary objective is to evaluate the effects of 3 oral dosages (2.5; 5; 7.5 mg b.i.d.) of ivabradine on heart rate, systolic and diastolic blood pressure, left ventricular volumes and function in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers.

Locations

• , , Germany
• , , Italy

Related clinical trials

• The HEARTFELT Study
• A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions
• Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
• The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)
• Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
• Mobile-Based Telemedicine and Health-Related Quality of Life Among Patients With Chronic Heart Failure (MOBILE-HF)

View on source registry